Tobias Bald

NK cell plas­tic­i­ty in cancer

Abstract 

Biography/​Link 

Tobias Bald, PhD, serves as Pro­fes­sor for Tumor Immuno­bi­ol­o­gy at the Insti­tute for Exper­i­men­tal Oncol­o­gy at the Uni­ver­si­ty Hos­pi­tal Bonn, Ger­many. He obtained his PhD with high­est hon­ors from the Fac­ul­ty of Med­i­cine at the Uni­ver­si­ty of Bonn in 2015, focus­ing on the role of inflam­ma­to­ry respons­es in melanoma pro­gres­sion and the sig­nif­i­cance of the type I IFN sys­tem in can­cer immunother­a­py effi­ca­cy. Fol­low­ing the receipt of an EMBO Long-term Fel­low­ship, dr. Bald joined dr. Mark Smyth’s lab at the Queens­land Insti­tute for Med­ical Research, Bris­bane, Aus­tralia, in 2016. 

In 2018, he was grant­ed an ear­ly career fel­low­ship, enabling him to estab­lish a junior group to inves­ti­gate the impact of the Nectin-Net­work in the tumor microen­vi­ron­ment. In 2020, dr. Bald became a mem­ber of the DFG clus­ter of excel­lence ImmunoSen­sa­tion and found­ed the Lab­o­ra­to­ry for Tumor Immuno­bi­ol­o­gy (www​.bald​lab​.com) at the Uni­ver­si­ty Hos­pi­tal Bonn. His research focus­es on under­stand­ing the reg­u­la­tion of tumor-infil­trat­ing immune cells to devel­op inno­v­a­tive can­cer therapies.